Head-to-head evidence
Insulin Lispro vs LY2963016
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
Insulin Lispro · Humalog
Marketed by Eli Lilly
NCT00551356 · Phase 3 · completed
The study was randomized and compared two active treatments, but it was open-label, enrolled 53 participants, and used a glucose-excursion measure rather than a hard clinical endpoint. Because the registry provides no results, it is not possible to determine whether the primary endpoint was met.
Next expected readout: December 2026 · NCT06251635 (registry estimate)
LY2963016 · Basaglar
Marketed by Eli Lilly
NCT01421459 · Phase 3 · completed
The study was randomized, triple-blind, and active-controlled, with 759 participants, but its primary endpoint was HbA1c, a laboratory surrogate rather than a hard clinical outcome. The prespecified non-inferiority comparison was met: the 95% confidence interval for the treatment difference remained below the +0.4% margin.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin Lispro's landscape · LY2963016's landscape